Follow
Keith Q. Tanis
Keith Q. Tanis
Principal Scientist, Merck & Co.
Verified email at merck.com
Title
Cited by
Cited by
Year
Transcriptional architecture of the primate neocortex
A Bernard, LS Lubbers, KQ Tanis, R Luo, AA Podtelezhnikov, EM Finney, ...
Neuron 73 (6), 1083-1099, 2012
2442012
Two distinct phosphorylation pathways have additive effects on Abl family kinase activation
KQ Tanis, D Veach, HS Duewel, WG Bornmann, AJ Koleske
Molecular and cellular biology, 2003
2002003
Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure
CJ Winrow, KQ Tanis, DR Reiss, AM Rigby, JM Uslaner, VN Uebele, ...
Neuropharmacology 58 (1), 185-194, 2010
1262010
Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging
AA Podtelezhnikov, KQ Tanis, M Nebozhyn, WJ Ray, DJ Stone, ...
PloS one 6 (12), e29610, 2011
972011
Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis
EG Stopa, KQ Tanis, MC Miller, EV Nikonova, AA Podtelezhnikov, ...
Fluids and Barriers of the CNS 15, 1-10, 2018
922018
Blood-gene expression reveals reduced circadian rhythmicity in individuals resistant to sleep deprivation
ES Arnardottir, EV Nikonova, KR Shockley, AA Podtelezhnikov, RC Anafi, ...
Sleep 37 (10), 1589-1600, 2014
822014
CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure
KQ Tanis, RS Duman, SS Newton
Biological psychiatry 63 (7), 710-720, 2008
802008
Intracellular signaling pathways pave roads to recovery for mood disorders
KQ Tanis, RS Duman
Annals of medicine 39 (7), 531-544, 2007
752007
Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development
KQ Tanis, SS Newton, RS Duman
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2007
692007
The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease
S Cazanave, A Podtelezhnikov, K Jensen, M Seneshaw, DP Kumar, ...
Scientific reports 7 (1), 17193, 2017
582017
Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms
X Cao, KQ Tanis, AJ Koleske, J Colicelli
Journal of biological chemistry 283 (46), 31401-31407, 2008
482008
Human Alzheimer’s disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology
SM Rothman, KQ Tanis, P Gandhi, V Malkov, J Marcus, M Pearson, ...
Journal of neuroinflammation 15, 1-15, 2018
452018
Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease
PE Cramer, RC Gentzel, KQ Tanis, J Vardigan, Y Wang, B Connolly, ...
Neurobiology of aging 64, 92-106, 2018
452018
Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity
EV Nikonova, Y Xiong, KQ Tanis, VL Dawson, RL Vogel, EM Finney, ...
Human molecular genetics 21 (1), 163-174, 2012
452012
Application of a rat liver drug bioactivation transcriptional response assay early in drug development that informs chemically reactive metabolite formation and potential for …
JJ Monroe, KQ Tanis, AA Podtelezhnikov, T Nguyen, SV Machotka, ...
Toxicological Sciences 177 (1), 281-299, 2020
322020
Analysis of target genes regulated by chronic electroconvulsive therapy reveals role for Fzd6 in depression
B Voleti, KQ Tanis, SS Newton, RS Duman
Biological psychiatry 71 (1), 51-58, 2012
302012
Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in …
W Kang, AA Podtelezhnikov, KQ Tanis, S Pacchione, M Su, KB Bleicher, ...
Toxicological Sciences 177 (1), 121-139, 2020
262020
Induction of Alzheimer’s‐like changes in brain of mice expressing mutant APP fed excess methionine
A McCampbell, K Wessner, MW Marlatt, C Wolffe, D Toolan, ...
Journal of neurochemistry 116 (1), 82-92, 2011
242011
Toxicogenomics in drug development: a match made in heaven?
C Qin, KQ Tanis, AA Podtelezhnikov, WE Glaab, FD Sistare, JJ DeGeorge
Expert Opinion on Drug Metabolism & Toxicology 12 (8), 847-849, 2016
232016
Quantitative transcriptional biomarkers of xenobiotic receptor activation in rat liver for the early assessment of drug safety liabilities
AA Podtelezhnikov, JJ Monroe, AG Aslamkhan, K Pearson, C Qin, ...
Toxicological Sciences 175 (1), 98-112, 2020
222020
The system can't perform the operation now. Try again later.
Articles 1–20